Orlando, Florida
CNS clinical trials in Orlando, FL
57 CNS studies are recruiting participants at sites in Orlando as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Orlando at a glance
- 57 studies are recruiting at a site in Orlando.
- By phase: Phase 1 (2), Phase 2 (17), Phase 3 (26), Phase 4 (4), No phase (4), Observational (4). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (51), university, hospital or other (6).
- By research area: Depression (21), Parkinson's Disease (10), Migraine (7), Multiple Sclerosis (6), Schizophrenia (5), ADHD (4), Epilepsy (3), Bipolar Disorder (1).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Orlando
Basic details from each study's public record (the 30 most recently updated of 57). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- CNS Healthcare of Orlando
- Registry record
- NCT07226661 · updated
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Seaport Therapeutics
- Study site
- Seaport Investigator Site
- Registry record
- NCT07065240 · updated
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Clinical Neuroscience Solutions, LLC (Orlando)
- Registry record
- NCT07592689 · updated
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
- No phase
- Ages 60 and older
- All sexes
- Sponsor
- AdventHealth
- Study site
- AdventHealth Neuroscience Institute
- Registry record
- NCT05877885 · updated
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Study site
- Clinical Neuroscience Solutions, Inc.
- Registry record
- NCT07284667 · updated
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- LivaNova
- Study sites
- APG Research, LLC · Nova Psychiatry Inc.
- Registry record
- NCT03887715 · updated
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Charter Research - Orlando
- Registry record
- NCT07412756 · updated
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- Phase 3
- Ages 10 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- APG Research LLC
- Registry record
- NCT06372964 · updated
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
- Observational
- From 18 months, up to 11 years
- All sexes
- Sponsor
- State University of New York at Buffalo
- Study site
- Nemours Foundation
- Registry record
- NCT07048574 · updated
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Charter Research Orlando
- Registry record
- NCT07716098 · updated
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Registry record
- NCT07621237 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Orlando, FL on ClinicalTrials.gov.
Schizophrenia studies recruiting in Orlando
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Phase 2
- Ages 55 to 90
- All sexes
- Sponsor
- MapLight Therapeutics
- Registry record
- NCT06887192 · updated
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Phase 3
- Ages 13 to 17
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Apg Research, Llc
- Registry record
- NCT07288567 · updated
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Apg Research, Llc
- Registry record
- NCT07424404 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Orlando, FL on ClinicalTrials.gov.
Bipolar disorder studies recruiting in Orlando
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Charter Research - Orlando
- Registry record
- NCT07286175 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Orlando, FL on ClinicalTrials.gov.
ADHD studies recruiting in Orlando
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
- Phase 3
- Ages 6 to 11
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717879 · updated
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717892 · updated
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Alkermes, Inc.
- Study site
- Alkermes Investigational Site
- Registry record
- NCT07755410 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Orlando, FL on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Orlando
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Orlando Health Cancer Institute ( Site 0012)
- Registry record
- NCT06841354 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)
- Registry record
- NCT06952504 · updated
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
- Observational
- Ages 50 to 85
- All sexes
- Sponsor
- CND Life Sciences
- Study site
- Neurology One
- Registry record
- NCT07428447 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study sites
- Advent Health Orlando · Charter Research - Winter Park/Orlando
- Registry record
- NCT07174310 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Neurology One
- Registry record
- NCT06680830 · updated
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
- Phase 2
- Ages 30 to 80
- All sexes
- Sponsor
- Appello Pharmaceuticals, Inc.
- Study site
- Neurology One (Site #205)
- Registry record
- NCT07432958 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Orlando, FL on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Orlando
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Zenas BioPharma (USA), LLC
- Study site
- Neurological Services of Orlando
- Registry record
- NCT07067463 · updated
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06433752 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Orlando, FL on ClinicalTrials.gov.
Epilepsy studies recruiting in Orlando
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- Orlando Health Neuroscience Institute
- Registry record
- NCT05667142 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Orlando, FL on ClinicalTrials.gov.
Migraine studies recruiting in Orlando
Study of EVO756 in Adults With Migraine
- Phase 2
- Ages 18 to 64
- All sexes
- Sponsor
- Evommune, Inc.
- Study site
- Clinical Neuroscience Solutions, Inc.
- Registry record
- NCT07616128 · updated
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Clinical Associates of Orlando, LLC
- Registry record
- NCT07816367 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Orlando, FL on ClinicalTrials.gov.
Ask about studies near Orlando
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Florida
All Florida locations
225 studies recruiting across 72 cities.
Miami
82 studies recruiting.
Tampa
70 studies recruiting.
Jacksonville
39 studies recruiting.
Hollywood
33 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections